Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | phosphodiesterase 4B, cAMP-specific | References | |
Homo sapiens | phosphodiesterase 4D, cAMP-specific | Starlite/ChEMBL | References |
Homo sapiens | phosphodiesterase 4C, cAMP-specific | References | |
Homo sapiens | phosphodiesterase 4A, cAMP-specific | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Carboxylesterase family protein | 0.1708 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1708 | 1 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.1708 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1708 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.1708 | 1 | 1 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0447 | 0.0413 | 0.0413 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0447 | 0.0413 | 0.0413 |
Echinococcus multilocularis | carboxylesterase 5A | 0.1708 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0447 | 0.0413 | 0.0413 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0447 | 0.0413 | 0.0413 |
Echinococcus granulosus | acetylcholinesterase | 0.1708 | 1 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.1708 | 1 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.1708 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.1708 | 1 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.1708 | 1 | 1 |
Giardia lamblia | CAMP-specific 3,5-cyclic phosphodiesterase 4B | 0.0447 | 0.0413 | 0.5 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0447 | 0.0413 | 0.0413 |
Toxoplasma gondii | 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein | 0.0447 | 0.0413 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.1708 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 2 mg kg-1 | Inhibition of lipopolysaccharide(LPS) stimulated TNF-alpha release in mice after peroral dose | ChEMBL. | 9873613 |
ED50 (functional) | = 2 mg kg-1 | Inhibition of lipopolysaccharide(LPS) stimulated TNF-alpha release in mice after peroral dose | ChEMBL. | 9873613 |
ED50 (functional) | = 10 mg kg-1 | Inhibition of streptococcal cell wall(SCW) induced arthritis in rat | ChEMBL. | 9873613 |
F (ADMET) | = 35 % | Bioavailability in mouse | ChEMBL. | 9873613 |
F (ADMET) | = 35 % | Bioavailability in mouse | ChEMBL. | 9873613 |
F (ADMET) | = 35 % | Oral bioavailability in mouse | ChEMBL. | 18686943 |
IC50 (binding) | = 42 nM | Inhibition of PDE4 from guinea pig macrophages | ChEMBL. | 9873613 |
IC50 (binding) | = 42 nM | Inhibition of PDE4 from guinea pig macrophages | ChEMBL. | 9873613 |
Ki (binding) | = 25 nM | Inhibition of Rolipram binding to PDE4 | ChEMBL. | 9873613 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.